Status:
RECRUITING
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
Lead Sponsor:
Hywel Dda Health Board
Collaborating Sponsors:
University of Aberdeen
Conditions:
Diabetic Retinopathy (DR)
Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-80 years
Brief Summary
Diabetes mellitus is a disorder of sugar and fat metabolism which results in damage to the small blood vessels in various organs, this includes the retina - the part of the eye that processes light in...
Detailed Description
Introduction Diabetic Retinopathy (DR) places a huge burden on ophthalmic clinical services throughout the world as one of the leading causes of reduced vision in working age adults \[1,2\]. This is ...
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes mellitus
- Male or female aged 18 - 80 inclusive
Exclusion
- Participant unable or unwilling to consent to inclusion in the study
- Prior treatment with intravitreal therapies for DMO
- Potential participant with a known infective disease that may put the study team at risk (eg. TB, HIV, hepatitis)
- Age 17 yo or less or 81 yo or older
- Known underlying genetic condition affecting lipid metabolism
Key Trial Info
Start Date :
March 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2030
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06914778
Start Date
March 31 2025
End Date
January 1 2030
Last Update
April 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince Philip Hospital
Llanelli, Wales, United Kingdom, SA14 8QF